Favorable ruling in NY state court for Pfizer in Celebrex case

World drug giant Pfizer says that a New York, USA, state court ruled that the plaintiffs suing it failed to present reliable scientific evidence necessary to prove that its COX-2 inhibitor Celebrex (celecoxib) can cause heart attacks and strokes at 200mg daily - the most commonly prescribed dosage of the painkiller. In her decision, Justice Kornreich held that "...with regard to Celebrex at 200mg/daily, the scientific evidence, whether for a heart attack or stroke, is just not there." The ruling follows a similar decision in November 2007 by the US District Court of Northern California in the Celebrex multi-district federal litigation. In the federal decision, the Court held there are "no randomized controlled trials or meta-analyses of such trials or meta-analyses of observational studies that find an association between Celebrex 200mg/day and a risk of heart attack or stroke."